Inclusion Criteria:  • Histologically proven cancer;  cancer-related pain corresponding to a site (or sites) of radiologically confirmed bone metastases with a severity score of at least 2 out of 10 according to the Brief Pain Inventory (NRS scale); age ≥ 18 years; indication for a palliative course of EBRT; osteolytic or mixed (osteoblastic/osteolytic) bone metastases ≤ 5 cm in the largest diameter; target tumours accessibility for device (ribs, extremities, pelvis, shoulders or posterior aspects of spinal vertebra) and at least 1 cm from skin and major nerve bundles;  Exclusion Criteria:  Inability to provide a written informed consent; Karnofsky performance status (KPS) < 60; presence of clinical or radiological evidence of spinal cord compression, a pathological fracture, or an impending fracture needing surgical fixation; previous EBRT to study site (or sites); participation in another clinical trial and any concurrent treatment with any investigational drug within 4 weeks prior to trial entry; inability to comply with study and follow up procedures; patients having metal implants, pacemakers or clustered markers non-MR compatible